AT THE BRAIN LEVEL.
needs predictive translational objective functional biomarkers
TRANSLATIONAL EEG biomarker
Using EEG recording, a closer look at the brain’s neural activity reveals excessive synchronization in the Beta frequency range of PD patients’ motor cortex.
These low frequencies (Beta waves) are transiently reduced by dopamine agonists such as L-DOPA. Likewise, the 6-OHDA rat model of Parkinson’s disease shows a stable and pharmacosensitive Beta signature in vivo, which makes it clinically-relevant for preclinical anti-PD compound testing.
Augment the predictability of your compound performance on PD syndrome with the 6-OHDA model and BetaPark!
BETApark is objective & stable over time
A stable and specific Beta oscillation (BetaPark) is found in the motor cortex of the unilateral 6-OHDA rat model of PD, as found in PD patients.
This translational biomarker is:
- Incredibly stable over time
- Objective, measured inside the motor cortex
- Exclusively revealed by Cue® and EEG
PHARMACOSENSITIVE biomarker of parkinson's disease
Modulated by a pharmacology of reference (Dopamine agonists), BetaPark is a pharmacosensitive biomarker,
BetaPark is expressed in the 6-OHDA rat model and is stable over time.
We quantify the pharmacodynamic effects of your compound in vivo, on BetaPark and objectively evaluate how it compares to reference drugs in acute or chronic paradigms.